SCHEMBL4808360

SCHEMBL4808360

COc1nc(Oc2cccc(C#N)c2)nc(-c2ccc(Cl)cc2Cl)c1-c1ccc(Cl)cc1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 14/20 0.52
CNR2 P34972 11/20 0.52
GSK3A P49840 1/20 0.43
GSK3B P49841 1/20 0.43
DYRK1A Q13627 1/20 0.43
CLK4 Q9HAZ1 1/20 0.43
ALDH1A1 P00352 2/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
SQOR Q9Y6N5 1/20 0.39
MDM2 Q00987 1/20 0.38
DPP4 P27487 1/20 0.38
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
MAPK1 P28482 1/20 0.37
CASP1 P29466 1/20 0.37
CYP2C19 P33261 1/20 0.37
CASP7 P55210 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4802298 0.92 CNR1 (0.54) CNR1CNR2GSK3AGSK3BDYRK1A
SCHEMBL4810139 0.85 CNR1 (0.56) CNR1CNR2DPP4CYP1A2CYP3A4
SCHEMBL4810614 0.81 CNR1 (0.42) CNR1CNR2GSK3AGSK3BDYRK1A
SCHEMBL4807595 0.81 CNR1 (0.55) CNR1CNR2DPP4
SCHEMBL4807155 0.80 CNR1 (0.46) CNR1CNR2GSK3AGSK3BDYRK1A
SCHEMBL30941215 0.80 CNR1 (0.46) CNR1CNR2GSK3AGSK3BDYRK1A
SCHEMBL4807031 0.80 CNR1 (0.53) CNR1CNR2GSK3AGSK3BDYRK1A
SCHEMBL4808021 0.79 CNR1 (0.43) CNR1CNR2GSK3AGSK3BDYRK1A
SCHEMBL4812430 0.78 CNR1 (0.52) CNR1CNR2ALDH1A1MAPTHPGD
SCHEMBL4810306 0.77 CNR1 (0.51) CNR1CNR2DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7405221-B2 Substituted pyrimidines MERCK & CO., INC. (US) 2008-07-29 US disclosed
US-20050245554-A1 Substituted pyrimidines MERCK SHARP & DOHME CORP. 2005-11-03 US disclosed
EP-1546115-A2 SUBSTITUTED PYRIMIDINES Merck & Co., Inc. (US) 2005-06-29 EP disclosed
WO-2004029204-A2 SUBSTITUTED PYRIMIDINES MERCK & CO., INC. (US) 2004-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245554-A1 Substituted pyrimidines CNR1, CNR2, GPR119 CNR1 1/4885CNR2 2/4885GSK3A 1632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.